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Abstract. Polymorphonuclear leukocyte (PMNL) infiltration is an important character-
istic in psoriatic lesions. Elevated concentrations of the chemoattractant eicosanoid leuko-
triene B4 (L TB4) are present in psoriatic skin. lts chemotactic activity is mediated via high 
affinity receptors on PMNL. The goal of our work was to ascertain whether PMNL infil-
tration in psoriasis can be accounted for by functional abnormalities of the circulating 
PMNL due to alterations in the LTB4 receptor density or affinity (or both). No significant 
difference was found between patients with psoriasis, healthy controls and patients with 
another inflammatory dermatosis (atopic eczema) with regard to the binding parameters of 
LTB4 receptors on PMNL. Our findings suggest that PMNL accumulation in psoriatic skin 
may be the result of an excess of cutaneous chemoattractant rather than the increased 
readiness of psoriatic PMNL to migrate towards L TB4 due to altered LTB4 receptor den-
sity or affinity. 
lntroduction 
In recent years, the knowledge about the 
arachidonic acid metabolism in skin has 
considerably increased. A very complex pic-
ture about the physiological and pathophysi-
ological role of arachidonic acid metabolites 
in skin has emerged. The 5- and 12-lipoxy-
genase products of ~rachidonic acid (L TB4 
and 12-HETE) appear to play an important 
role in the pathophysiology of common in-
flammatory and hyperproliferative skin dis-
eases such as psoriasis and atopic eczema as 
can be deduced from the following Observa-
tions: 
(I) In involved psoriatic skin the Ievels 
ofLTB4 and 12-HETE are increased [1-3]. 
(2) After topical application, L TB4 and 12-
HETE have been shown to induce leukocyte 
chemotaxis, inflammatory infiltration of the 
skin, intraepidermal neutrophil infiltrate 
and epidermal hyperplasia [ 4-7). (3) Gluco-
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corticosteroids, the most potent anti-inflam-
matory drugs in dermatology, inhibit the re-
lease of arachidonic acid from the cellular 
phospholipids [8] and consequently the for-
mation of LTB4 and 12-HETE. (4) Indome-
tacin, a known cyclooxygenase inhibitor, re-
directs arachidonic acid into lipoxygenase 
products and exacerbates psoriasis (9, 1 0]. 
(5) The topical application ofRS-43179 (lon-
apalene), an inhibitor of 5-lipoxygenase, has 
been shown to clear psoriatic lesions [ 11 ]. 
L TB4 is the most potent polymorphonu-
cJear Jeukocyte (PMNL) chemotactic factor 
generated by the lipoxygenation of arachi-
donic acid [ 12]. Chemotactic activity of 
PMNL is mediated by specific L TB4 recep-
tors [ 13]. Cutaneous infiltration of PMNL is 
assumed to be an important early event in 
the pathogenesis of psoriasis [ 14]. 
The goal of the present investigation was 
therefore to ascertain whether the intraepi-
dermal accumulation of PMNL in psoriasis 
can be accounted for by functional abnor-
malities of the circulating PMNL due to 
alterations in the LTB4 receptor density or 
affinity (or both). Forthis purpose, we mea-
sured the binding of L TB4 to PMNL in 
patients with psoriasis, and compared these 
findings with those in another chronic in-
flammatory dermatosis (atopic eczema) and 
healthy controls. 
Materials and Methods 
Patients 
Eleven patients with psoriasis ( 10 males, 1 female; 
32-82 years of age), 10 patients with atopic eczema (6 
males, 4 females; 12-67 years of age), and 11 healthy 
volunteers (4 males, 7 females; 21-49 years of age) 
participated in the study. 
The psoriasis group consisted of 6 patients with 
the plaque type, 4 patients with the guttate type, and 1 
patient with erythrodennic psoriasis. 
M eier/Gross/Klotz/Ruzicka 
The extent of cutaneous involvement was I 0-
25% of the body surface in 3 psoriasis and 5 atopic 
eczema patients, and greater than 25% in 8 patients 
with psoriasis and 5 patients with atopic eczema, 
respecti vely. 
Excluded from the study were patients who bad 
received systemic treatment or phototherapy for their 
skin disease within the previous 4 weeks. 
Preparation of PMNL 
PMNL were isolated as previously described [ 15]. 
Briefly, 40 ml of heparinized blood was centrifuged at 
150 g for 15 min at room temperature. The pJatelet-
rich plasma was discarded, the cell pellet was sus-
pended in saline and layered over a discontinuous Per-
co11 gradient (Pharmacia, Freiburg, FRG). After cen-
trifugation at 1 ,450 g for 20 min at 14 o C the PMNL 
layer was taken ofT and washed with saline. Erythro-
cytes were removed by hypotonic Iysis with distilled 
water, platelets by repeated centrifugation in bovine 
serum albumin solution (Sigma, Deisenhofen, FRG). 
The final PMNL pellet was resuspended in Hanks' bal-
anced salt solution with phenol red (HBSS; Flow, 
Meckenheim, FRG) containing I 0 mM Hepes buffer 
(pH 7.3; Flow). The resultingcell suspension contained 
more than 90 o/o neutrophils with a viability of greater 
than 95% as assessed by trypan blue exclusion. 
Measurement ofthe Binding off3H]LTB4IO 
PMNL 
[5,6,8,9,11,12,14,15-JH(N)]-leukotriene B4 (spe-
cific activity 200 Ci/mmol) was purchased from New 
England Nuclear (Dreieich, FRG). PMNL were incu-
bated with increasing concentrations of [3H]LTB4 to 
determine the dissociation constant Kt and the recep-
tor density of the cells. Final [3H]L TB4 concentra-
tions were in the range of 0.1-2 nM. Increasing con-
centrations of [3H]L TB4 were pipetted into Eppen-
dorf tubes and evaporated und er a stream of nitrogen. 
Then aliquots of PMNL suspension ( 106 cells/200 J.Ll 
buffer) were added to start the incubation which was 
performed for 40 min at 4 oc. At this temperature, 
negligible amounts of [3H]LTB4 were metabolized to 
oxygenated products as assessed by reversed-phase 
HPLC (data not shown). Nonspecific binding was 
determined in the presence of 2 J.1M unlabelled L TB4 
(Paesel, Frankfurt, FRG) which was pipetted and 
evaporated together with [3H]LTB4• Specific binding 
was defined as total binding (measured in the absence 
of unlabelled L TB4) minus nonspecific binding. 
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Fig. 1. Specific (o) and nonspe-
cific (o) binding of [3H]LTB4 to 
PMNL as a function of increasing 
concentrations of [3H]LTB4 • Each 
point represents the mean of dupli-
cate measurements. The inset 
shows the Scatchard plot derived 
from the specific binding data. 
Curve fitting according to a one-site 
model revealed a. ~ of 0.76 nM 
and a receptor density of 14,316 
sites/cell. 
After incubation, cells were harvested on glass 
fiber filtermats (Skatron, Düsseldorf, FRG) using a 
Skatron cell harvester, and washed for 7 s with cold 
buffer. The filters were then placed into plastic vials 
containing 2 ml scintillation fluid (Scintillator 299™, 
Packard, Frankfurt, FRG), and the radioactivity re-
tained in the filters was determined in a TRI-CARB 
liquid scintillation counter (Packard, Frankfurt, 
FRG). 
Analysis of Binding Data 
All binding experiments were done in duplicate. 
Computeranalysis of binding data was performed by 
nonlinear curve-fitting with a modification ofthe pro-
gram SCTFIT [16]. 
Assessment of statistical differences between the 
proband groups was achieved using the nonparamet-
ric Mann-Whitney test. 
Results 
Figure 1 illustrates the speciiic binding of 
[3H]LTB4 to PMNL as a function of increas-
ing concentrations of [3H]LTB4• Curve fit-
ting assuming the presence of a singledass of 
binding sites gave a ~ of 0. 76 nM and a 
receptor density of 14,316 sites/cell in the 
shown example. Curve fitting according to a 
two-site model did not improve the fit. Con-
sequently, a linear Scatchard plot could be 
deri ved from the data, suggesting that 
[3H]LTB4 interacts with a single class of 
binding sites under the experimental condi-
tions used. 
Table 1 summarizes the binding parame· 
ters (i.e. receptor affinity expressed as ~ in 
nM. and receptor density expressedas num· 
ber of receptors per cell) for L TB4 receptors 
on PMNL in patients with psoriasis and 
atopic eczema compared to healthy controls. 
PMNL from healthy controls expressed 
LTB4 receptors with a ~ of 0.97 ± 0.29 nM 
and a density of 13,400 ± 3, 770 receptors/ 
cell. Virtually identical results were obtained 
with PMNL from patients with psoriasis and 
atopic eczema. Their LTB4 receptors re-
vealed a ~ of0.85 ± 0.23 nM and a density 
of 13,800 ± 4,360 receptors/cell in psoriasis 
and a K<t of0.82 ± 0.27 nM, and a density of 
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Table I. Binding parameters (means of duplicate 
measurements) of L TB4 receptors on PMNL in pa-: 
tients with psoriasis, atopic eczema and healthy con-
trols 
Diagnosis and 
patient No. 
PsoFiasis 
Plaque type 
J 
2 
3 
4 
5 
6 
Guttate type 
7 
8 
9 
10 
Eryth rodermic 
I 1 
Atopic eczema 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
Psoriasis 
(n = 11) x ± SD 
Atopic eczema 
(n = 1 0) x ± SD 
Controls 
(n = 11) x ± SD 
Receptor 
affinity 
~.nM 
0.70 
0.96 
0.70 
0.75 
0.56 
0.76 
1.22 
1.06 
1.23 
0.71 
0.64 
1.08 
0.80 
0.84 
0.72 
0.67 
1.11 
0.46 
1.27 
0.79 
0.42 
0.85 ±0.23 
0.82±0.27 
0.97±0.29 
Receptor 
density 
sites/cell 
19,876 
11 ,4 71 
15,991 
14,789 
8,336 
14,316 
10,654 
15,886 
17,808 
16,819 
5,306 
19,671 
16,600 
16,321 
12,459 
15,446 
19,163 
12,785 
7,928 
9,672 
8,114 
13,800 ± 4,360 
1 3' 8 00 ± 4, 31 0 
I 3,400 ± 3, 770 
Meier/Gross/Klotz/Ruzicka 
13,800 ± 4,31 0 receptors/cell in atopic ecze-
ma. The difference between healthy controls 
and patients with psoriasis or atopic eczema 
was statistically not significant. Within the 
psoriasis group, binding parameters did not 
differ significantly between patients with 
plaque and guttate types of psoriasis. The 
only patient with erythrodermic psoriasis, 
~owever, exhibited a ~ of 0.67 nM and a 
remarkably low density of 5,306 receptors/ 
cell, the lowest nurober measured in any of 
our probands. No correlation was observed 
between LTB4 receptor affinity or density 
and the severity or extent of psoriasis and 
atopic eczema (data not shown). 
Discussion 
Psoriatic lesions are characterized, 
among others, by a pronounced inflamma-
tory infiltrate which may be, at least partly, 
caused by the chemotactic activity of lipoxy-
genase-derived eicosanoids since elevated 
Ievels of LTB4 and 12-HETE were identified 
in psoriatic skin [ 1-3]. The goal of the 
present investigation was to ascertain 
whether the inflammatory changes in psoria-
sis may also be accounted for by functional 
abnormalities of the circulating PMNL due 
to alterations in the LTB4 receptor density or 
affinity (or both). Forthis purpose, we per-
formed radioligand binding studies in 
PMNL of patients with different types of 
psoriasis. For comparison, we studied a 
group of patients with another inflammatory 
dermatosis (atopic eczema) and healthy con-
trols. 
Using classical radioligand binding assays 
for the detection of cell surface receptors, we 
were able to demonstrate the presence of 
high·affinity LTB4 receptors on PMNL. 
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Their mean ~ was 0. 97 nM, and there were 
13,400 binding sites/cell. This is within the 
range reported in the Iiterature [ 17, 18]. U n-
like previous workers, we were unable to 
measure low-affinity binding sites. This may 
be due to our method of separation of recep· 
tor-bound from free radioligand since the 
separation time of 7 s by vacuum filtration 
may be sufficient to dissociate ligands from 
low-affinity receptors. The allowable separa-
tion time at a K<t of 1 o-7 nM, for example, is 
only 0.1 s [ 19]. On the other hand, there are 
widely varying results in the Jiterature con-
ceming binding characteristics of L TB4 to 
PMNL [17-21], and some other groups were 
also unable to confirm the presence of low 
affinity binding sites [20, 21 ]. Furthermore, 
PMNL chemotaxis is mediated by the high-
affinity subset of receptors [ 13] which seems 
thus of greater biologic relevance with regard 
to psoriasis than the low-affinity compo-
nent. 
No significant difference was found be-
tween healthy controls, patients with psoria-
sis and atopic eczema wi th regard to their 
L TB4 binding parameters. The mean recep-
tor affinities and densities were virtually 
identical in the three groups of probands. 
Closer analysis of binding data within the 
groups showed no correlation between the 
L TB4 receptor affinity or density and type, 
severity or extent of psoriasis and atopic 
eczema. However, this ana1ysis depends on a 
small nurober of subjects, and requires con-
firmation in greater subgroups of patients. 
However, it was conspicuous that the only 
patient with erythrodermic psoriasis, whom 
we had the opportunity to examine, dis-
played by far the lowest nurober of receptors 
per cell (5,306 compared to 13,400 in 
healthy controls and 13,800 in psoriatic pa-
tients). The receptor affinity was within nor-
mal range in this person. This finding may 
be chance or reflect down regulation of LTB4 
receptors in the most severely affected pa-
tient. A final answer to this question requires 
analysis of a greater number of patients with 
psoriatic erythroderma which is in pro· 
gress. 
So far, no other studies of eicosanoid 
receptors in psoriasis and atopic eczema 
have been published. Our results, however, 
complement findings of normal chemotactic 
response of psoriatic PMNL to LTB4 [22, 
23], suggesting that the accumulation of 
PMNL in psoriatic skin may be the result of 
an excess of cutaneous chemoattractant, 
rather than reflecting the increased readiness 
of psoriatic PMNL to migrate towards a che-
motactic stimulus. Indeed, e1evated cuta-
neous Ievels of the chemoattractant eicosa-
noids LTB4 and 12-HETE were identified in 
psoriasis and atopic eczema [1-3, 24]. In 
addition, enhanced 5-lipoxygenase activity 
was found in skin of psoriatic patients [25] 
although peripheral PMNL of these patients 
display normal 5-lipoxygenase activity [ 15]. 
Thus, it is likely that elevated cutaneous Iev-
els of chemoattractant eicosanoids may play 
a role in the initiation of the inflammatory 
infiltrate in both dermatoses, and that eico-
sanoids released from infiltrating inflamma-
tory cells may contribute to the maintenance 
of the inflammatory infiltrate and the hyper-
prol~feration observed in chronic inflamma-
tory skin diseases [7]. On the other band, the 
altered responsiveness of monocytes from 
patients with psoriasis and atopic eczema 
towards L TB4 as demonstrated by Czar-
netzki [26] 1eaves open the question of possi-
ble abnormalities of LTB4 receptors on cell 
types other than PMNL. 
Our findings of normal LTB4 receptor af-
finity and density and normal 5-lipoxygen-
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ase activity [ 15] of PMNL do not support the 
hypothesis of an intrinsic defect in the eico-
sanoid metabolism of psoriatic PMNL. Sti11, 
however, agents interfering with LTB4 recep-
tors seem to be a promising therapeutic ap-
proach in psoriasis. 15-HETE, for exampJe, 
was recently reported to inhibit LTB4-in-
duced chemotaxis of PMNL, possibly by re-
ceptor antagonism [27]. This eicosanoid dis-
plays antipsoriatic properties when injected 
intra1esional1y [28]. Taking into consider-
ation our recent identification of LTB4 and 
12-HETE receptors on keratinocytes [29, 
30], the use of eicosanoid receptor antago-
nists in inflammatory and hyperproliferative 
skin diseases seems of even greater interest. 
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